Author of

• 25953

  +

  P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 965)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27291

    +

    P2.16-33 - Adenosquamous Carcinoma of the Lung: Comparison of Surgical Outcomes with Squamous Cell and Adenocarcinoma (ID 14235)

    16:45 - 18:00  |  Author(s): Gamze Çetinkaya
    • Abstract

    Background
    

    Lung adenosquamous carcinoma (ASC) is a rare subtype of lung cancer that contains squamous cell carcinoma (SCC) and adenocarcinoma (AC) components. Clinical and prognostic features have not been fully established. The aim of the study is to compare the clinical characteristics and survival outcomes of ASC, AC and SCC.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    In our clinic, the data of 1076 patients who underwent segmentectomy, lobectomy, or pneumonectomy due to non-small cell lung cancer between 1996-2016 was recorded prospectively and reviewed retrospectively. Patients with histologically proven tumor cell type ASC (n = 25, 2,32%), AC (n = 350, 32,52%) and SCC (n = 740, 50,18%) were included in the study. Univariate and multivariate analysis were performed to determine prognostic factors. The Kaplan-Meier method was used for survival analysis.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Our study group consisted of 915 patients (834 (91.15%) male, mean age 60.87 ± 9.02 (30-87) years). 65 (7,1%) patient underwent segmentectomy, 711 (77,7%) lobectomy and 139 (15,2%) pneumonectomies were performed as lung resections. Morbidity was seen in 326 patients (35.6%). Postoperative 90-day mortality rate was 2.95% (n = 27). When the demographic data was analyzed between the three groups, female gender was 18% in AC and 4% and 3.1% in ASC and SCC, respectively (p <0.001). In the preoperative positron emission tomography, the maximum standard uptake median value was 13,47 in SCC and 11,73 and 9,40 in ASC and AC, respectively (p <0.001). Pneumonectomy rate was 20.74% in SCC and 16% and 6.57% in ASC and AC, respectively (p <0.001). Early stage (stage 1) patients were 41.4% in the AC group and 28% and 35.7% in ASC and SCC respectively. While the presence of lymphatic metastasis was 36% in the ASK group; the rates were 31.7% and 29.6% in AC and SCC, respectively (p = 0.675). There was no statistically significant difference between the groups in terms of survival (p = 0.659, graph 1) after weighted Log-Rank test using Propensity score weights calculated for each cell type in case of more than two groups.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    ASCs are rare, malignant tumors that includes features of SCC and AC cell types, and frequently involves lymphatic metastases. However, there was no difference in survival when compared with AC and SCC.

    6f8b794f3246b0c1e1780bb4d4d5dc53